JP2010513356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513356A5 JP2010513356A5 JP2009541897A JP2009541897A JP2010513356A5 JP 2010513356 A5 JP2010513356 A5 JP 2010513356A5 JP 2009541897 A JP2009541897 A JP 2009541897A JP 2009541897 A JP2009541897 A JP 2009541897A JP 2010513356 A5 JP2010513356 A5 JP 2010513356A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid dispersion
- composition according
- carrier
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007962 solid dispersion Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- -1 inert filers Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000000725 suspension Substances 0.000 claims 5
- CZRKBWYUKKBUMS-HNNXBMFYSA-N (4r)-4-[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-5-(3,4-dichlorophenyl)pent-2-enoic acid Chemical compound C([C@@H](N(C)C(=O)C=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C=CC(O)=O)C1=CC=C(Cl)C(Cl)=C1 CZRKBWYUKKBUMS-HNNXBMFYSA-N 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920000856 Amylose Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical group CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000005426 pharmaceutical component Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 5
- 230000009278 visceral effect Effects 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 101800000399 Neurokinin A Proteins 0.000 description 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
- 102400000097 Neurokinin A Human genes 0.000 description 1
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 1
- 102000046798 Neurokinin B Human genes 0.000 description 1
- 101800002813 Neurokinin-B Proteins 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06126964A EP1938804A1 (en) | 2006-12-22 | 2006-12-22 | Pharmaceutical formulation comprising neurokinin antagonist |
| PCT/EP2007/011293 WO2008077591A2 (en) | 2006-12-22 | 2007-12-20 | Pharmaceutical formulation comprising neurokinin antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513356A JP2010513356A (ja) | 2010-04-30 |
| JP2010513356A5 true JP2010513356A5 (https=) | 2011-02-10 |
Family
ID=37762542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541897A Pending JP2010513356A (ja) | 2006-12-22 | 2007-12-20 | ニューロキニンアンタゴニストを含む製剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20100015225A1 (https=) |
| EP (2) | EP1938804A1 (https=) |
| JP (1) | JP2010513356A (https=) |
| KR (1) | KR20090092288A (https=) |
| CN (1) | CN101541309A (https=) |
| AR (1) | AR064622A1 (https=) |
| AU (1) | AU2007338359B2 (https=) |
| BR (1) | BRPI0720937A2 (https=) |
| CA (1) | CA2672402A1 (https=) |
| CL (1) | CL2007003767A1 (https=) |
| CO (1) | CO6180497A2 (https=) |
| EA (1) | EA200900827A1 (https=) |
| EC (1) | ECSP099450A (https=) |
| GT (1) | GT200900173A (https=) |
| IL (1) | IL198780A0 (https=) |
| MA (1) | MA31004B1 (https=) |
| MX (1) | MX2009006747A (https=) |
| MY (1) | MY145919A (https=) |
| NO (1) | NO20092722L (https=) |
| NZ (1) | NZ576987A (https=) |
| PE (1) | PE20081848A1 (https=) |
| TN (1) | TN2009000253A1 (https=) |
| TW (1) | TW200848056A (https=) |
| WO (1) | WO2008077591A2 (https=) |
| ZA (1) | ZA200903271B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201309635A (zh) * | 2006-02-10 | 2013-03-01 | Dow Agrosciences Llc | 殺蟲性之ｎ-取代（６-鹵烷基吡啶-３-基）烷基磺醯亞胺（二） |
| JPWO2010092925A1 (ja) * | 2009-02-12 | 2012-08-16 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
| US20120077803A1 (en) * | 2009-02-24 | 2012-03-29 | Novartis Ag | Uses Of NK Receptor Antagonists |
| US8263119B2 (en) * | 2010-12-01 | 2012-09-11 | Shire Llc | Capsule formulations containing lanthanum compounds |
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| MX2017011469A (es) * | 2015-03-10 | 2018-01-23 | Shionogi Inc | Dispersiones sólidas. |
| SG10202012002TA (en) | 2015-05-11 | 2021-01-28 | Lundbeck La Jolla Research Center Inc | Methods of treating inflammation or neuropathic pain |
| ES3063790T3 (en) | 2015-06-09 | 2026-04-20 | Lonza Sales Ag | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| KR20190085046A (ko) * | 2016-11-16 | 2019-07-17 | 어바이드 테라퓨틱스, 인크. | 약학 제제 |
| DK3541807T3 (da) | 2016-11-16 | 2021-12-06 | H Lundbeck As | Krystallinsk form af en magl-inhibitor |
| IL297470A (en) | 2020-04-21 | 2022-12-01 | H Lundbeck As | Synthesis of a monoacylglycerol lipase inhibitor |
| CN111904960A (zh) * | 2020-05-19 | 2020-11-10 | 合肥合源药业有限公司 | 一种固体分散体及药用组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622677A (en) * | 1969-07-07 | 1971-11-23 | Staley Mfg Co A E | Compressed tablets containing compacted starch as binder-disintegrant ingredient |
| JPH054919A (ja) * | 1990-07-25 | 1993-01-14 | Sankyo Co Ltd | チアゾリジン誘導体の固体分散体 |
| MY132550A (en) * | 1996-08-22 | 2007-10-31 | Novartis Ag | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists |
| KR20010023729A (ko) * | 1997-11-03 | 2001-03-26 | 디르크 반테 | 지질 저하제 조성물 |
| ME00189B (me) * | 1998-03-26 | 2011-02-10 | Astellas Pharma Inc | Preparati sa neprekidnim oslobađanjem |
| US20010053791A1 (en) * | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
| JP2004131393A (ja) * | 2002-10-08 | 2004-04-30 | Kowa Co | 易溶出性製剤 |
| GB2394417A (en) * | 2002-10-24 | 2004-04-28 | Novartis Ag | Solid dispersion comprising a piperidine substance P antagonist and a carrier |
| EP1686985A2 (en) * | 2003-10-27 | 2006-08-09 | Novartis AG | Use of neurokinin antagonists in the treatment of urinary incontinence |
| GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
| KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
| WO2006112649A1 (en) * | 2005-04-20 | 2006-10-26 | Ctc Bio, Inc. | Pharmaceutical composition containing sibutramine free base and manufacturing method thereof |
-
2006
- 2006-12-22 EP EP06126964A patent/EP1938804A1/en not_active Ceased
-
2007
- 2007-12-20 US US12/520,312 patent/US20100015225A1/en not_active Abandoned
- 2007-12-20 NZ NZ576987A patent/NZ576987A/en not_active IP Right Cessation
- 2007-12-20 AR ARP070105788A patent/AR064622A1/es not_active Application Discontinuation
- 2007-12-20 MX MX2009006747A patent/MX2009006747A/es not_active Application Discontinuation
- 2007-12-20 MY MYPI20092111A patent/MY145919A/en unknown
- 2007-12-20 JP JP2009541897A patent/JP2010513356A/ja active Pending
- 2007-12-20 CA CA002672402A patent/CA2672402A1/en not_active Abandoned
- 2007-12-20 WO PCT/EP2007/011293 patent/WO2008077591A2/en not_active Ceased
- 2007-12-20 AU AU2007338359A patent/AU2007338359B2/en not_active Ceased
- 2007-12-20 EA EA200900827A patent/EA200900827A1/ru unknown
- 2007-12-20 CN CNA2007800435054A patent/CN101541309A/zh active Pending
- 2007-12-20 KR KR1020097012819A patent/KR20090092288A/ko not_active Withdrawn
- 2007-12-20 BR BRPI0720937-1A patent/BRPI0720937A2/pt not_active IP Right Cessation
- 2007-12-20 EP EP07857016A patent/EP2117511A2/en not_active Withdrawn
- 2007-12-21 TW TW096149580A patent/TW200848056A/zh unknown
- 2007-12-21 CL CL200703767A patent/CL2007003767A1/es unknown
-
2008
- 2008-01-02 PE PE2008000080A patent/PE20081848A1/es not_active Application Discontinuation
-
2009
- 2009-05-12 ZA ZA200903271A patent/ZA200903271B/xx unknown
- 2009-05-14 IL IL198780A patent/IL198780A0/en unknown
- 2009-06-17 MA MA32008A patent/MA31004B1/fr unknown
- 2009-06-17 CO CO09062883A patent/CO6180497A2/es not_active Application Discontinuation
- 2009-06-19 TN TNP2009000253A patent/TN2009000253A1/fr unknown
- 2009-06-19 GT GT200900173A patent/GT200900173A/es unknown
- 2009-06-22 EC EC2009009450A patent/ECSP099450A/es unknown
- 2009-07-17 NO NO20092722A patent/NO20092722L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513356A5 (https=) | ||
| JP6612200B2 (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
| KR20090042967A (ko) | 플리반세린 제형 및 이의 제조방법 | |
| US8449896B2 (en) | Pharmaceutical composition having improved solubility | |
| AU2002359857B8 (en) | A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof | |
| WO2013146917A1 (ja) | 酸型カルボキシメチルセルロースを含む崩壊性粒子組成物の製造方法、並びに、該組成物及び該組成物を含む口腔内崩壊錠剤 | |
| EP2540318A1 (en) | Sustained-release solid preparation for oral use | |
| EP2540294B1 (en) | Sustained-release solid preparation for oral use | |
| US20080194638A1 (en) | Bioavailable formulations of heterocyclic compounds | |
| EP1738754B1 (en) | Solid pharmaceutical preparation | |
| AU2005338461A1 (en) | Pharmaceutical compositions of telmisartan | |
| TW202200123A (zh) | 一種複合物的藥物組合物及其製備方法 | |
| KR20140046217A (ko) | 프란루카스트-함유 고형 제제의 제조방법 | |
| KR101346453B1 (ko) | 텔리트로마이신을 포함하는 고상 제약 조성물 | |
| US12285411B2 (en) | Pharmaceutical composition comprising eluxadoline, process of preparation and use thereof | |
| EP1797872A1 (en) | Telmisartan-containing pharmaceutical compositions for oral intake | |
| JP2019526641A (ja) | テソフェンシン組成物 | |
| AU2002333235B2 (en) | Pharmaceutical formulation containing an LTB4 antagonist | |
| US20030119901A1 (en) | Pharmaceutical formulation containing an LTB4 antagonist | |
| KR101136075B1 (ko) | 고혈압 치료제 조성물 | |
| AU2024324576A1 (en) | Pharmaceutical formulations of gpr119 agonists and uses thereof | |
| WO2024261701A1 (en) | Edoxaban formulation. | |
| KR20060125805A (ko) | 고체 약제학적 제제 형태 | |
| WO2022132067A1 (en) | Stable bilayer tablet compositions | |
| WO2022115057A1 (en) | Improved manufacturing method for the formulations comprising vortioxetine hbr butanol solvate form h |